Canada Life
RLMD icon

Canada Life’s Relmada Therapeutics RLMD Stock Holding History

Canada Life’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-840
Closed -$31K – 2378
2022
Q3 		$31K Hold
840
– – ﹤0.01% 2180
2022
Q2 		$16K Hold
840
– – ﹤0.01% 2307
2022
Q1 		$24K Hold
840
– – ﹤0.01% 2323
2021
Q4 		$19K Hold
840
– – ﹤0.01% 2389
2021
Q3 		$22K Hold
840
– – ﹤0.01% 2412
2021
Q2 		$27K Hold
840
– – ﹤0.01% 2427
2021
Q1 		$29K Hold
840
– – ﹤0.01% 2450
2020
Q4 		$27K Hold
840
– – ﹤0.01% 2490
2020
Q3 		$31K Hold
840
– – ﹤0.01% 2316
2020
Q2 		$37K Buy
+840
New +$35.5K ﹤0.01% 2330

Other funds holding RLMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Canada Life's RLMD Position: Q4 2022 in Review

Canada Life sold out of Relmada Therapeutics (RLMD) in Q4 2022, closing a stake of 840 shares — an estimated $31K sold.

Canada Life first reported a position in RLMD in Q2 2020 and held it in 10 quarters. The position peaked at $37K in Q2 2020. 110 funds tracked by Wall St. Rank hold RLMD as of Q4 2022.

  • Canada Life reported no remaining Relmada Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Canada Life sold 840 Relmada Therapeutics shares in Q4 2022, an estimated $31K.
  • Canada Life first reported a position in Relmada Therapeutics in Q2 2020 and held it in 10 quarters.
  • Canada Life's Relmada Therapeutics position peaked at $37K in Q2 2020.
  • 110 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2022.

Based on Canada Life's 13F filing for Q4 2022, filed 10 Feb 2023.